CG
FPRX

Cutler Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Cutler Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,300
Closed -$9K – 5032
2019
Q1 		$9K Buy
5,300
+2,500
+89% +$28.5K ﹤0.01% 2601
2018
Q4 		$10K Buy
+2,800
New +$33.3K ﹤0.01% 2564
2018
Q2 		– Sell
-700
Closed -$1K – 5183
2018
Q1 		$1K Buy
+700
New +$13.7K ﹤0.01% 4254
2017
Q3 		– Sell
-6,800
Closed -$65K – 7066
2017
Q2 		$65K Buy
6,800
+3,000
+79% +$93.6K ﹤0.01% 2239
2017
Q1 		$42K Buy
+3,800
New +$167K ﹤0.01% 2599
2016
Q4 		– Sell
-1,500
Closed -$2K – 7645
2016
Q3 		$2K Buy
1,500
+200
+15% +$9.55K ﹤0.01% 5894
2016
Q2 		$11K Sell
1,300
-17,800
-93% -$774K ﹤0.01% 4067
2016
Q1 		$46K Sell
19,100
-19,100
-50% -$656K ﹤0.01% 2425
2015
Q4 		$69K Buy
+38,200
New +$1.28M ﹤0.01% 2132

Cutler Group's FPRX Position: Q2 2021 in Review

Cutler Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,200 shares — an estimated $82K sold.

Cutler Group first reported a position in FPRX in Q4 2015 and held it in 15 quarters. The position peaked at $496K in Q1 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Cutler Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 2,200 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $82K.
  • Cutler Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
  • Cutler Group's Five Prime Therapeutics, Inc. position peaked at $496K in Q1 2016.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.